info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Mucormycosis Companies

Mucormycosis companies specialize in addressing mucormycosis, a rare but serious fungal infection that primarily affects individuals with weakened immune systems. These companies contribute to infectious disease management by providing antifungal medications, diagnostic tools, and treatment options for mucormycosis.

Mucormycosis Key CompaniesLatest Mucormycosis Companies Update

Zydus Cadila to market TLC's mucormycosis drug in India:The Ahmedabad-based pharmaceutical company has entered into an agreement with Taiwan-based TLC to market AmphoTLC, a liposomal amphotericin B injection used to treat mucormycosis. This will help address the acute shortage of the drug in India.


Cadila Healthcare gains on agreement to market black fungus drug Shares of Cadila Healthcare rose after the company announced that it has entered into an agreement with TLC to market AmphoTLC in India. The drug is expected to address the country's shortage of liposomal amphotericin B, which is used to treat mucormycosis.


Black fungus drug news:Cipla launches Isavuconazole for mucormycosis treatment a leading Indian pharmaceutical company, has launched Isavuconazole, a new drug for the treatment of mucormycosis. The drug is expected to be a valuable addition to the limited treatment options available for this fungal infection.List of Mucormycosis Key Companies in the Market



  • Abbott Laboratories (U.S.)

  • Biocon Limited (India)

  • Cadila Pharmaceuticals Limited (India)

  • Novartis AG (Switzerland)

  • F. Hoffmann-La Roche (Switzerland)

  • Merck Sharp and Dohme (U.S.)

  • Mylan Labs (U.S.)

  • Bristol Myers Squibb (U.S.)

  • Bayer AG (Germany)

  • Lonza Group (Switzerland)

  • Sanofi (France)

  • Johnson & Johnson (U.S.)

  • Pfizer Inc. (U.S.)

  • Gilead Sciences (U.S.)


Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.